Abstract

  A lot of troubles we are facing as neurological surgeons when we deal with this tumor. Although it’s a benign tumor histologically, it has a malignant cellular characteristic, causes a big trouble in surgery and postsurgical treatment. It is divided into two types: adamantinomatous and papillary craniopharyngioma. The first surgical techniques for craniopharyngioma originated in 1891 by Selke. There is consensus that best management is surgery but there is trend developed recently between surgeons which is that subtotal resection is better to maintain function of surrounding structures, also total removal of this tumor surgically is challenging because of tight adherence of its capsule to lot of very important structures, In Best surgical hands this tumor is not favorable for resection because of multiple functional complications intraoperative and postoperative. Endocrine abnormalities are commonly seen postoperatively in the form of hypopituitarism. Immunotherapy including EGFR inhibitors such gefitinib, erlotinib, and lapatinib are now off-label use in treatment of craniopharyngiomas. In 2019 Rao., et al. reported treated case with selective BRAF inhibitor dabrafenib. Till now we didn’t reach the ideal management for this benign tumor although surgery is the best. we need to take a different step in the direction of searching for better management of this tumor.

Aim and Type: This is short review to search in literature about ideal management for adult craniopharyngioma and what is the next step that we should talk to get better outcome.

Methodology: Different online medical databases have been reviewed to search for best management of this tumor including PubMed and Cochrane and authors surgical team experience 

Conclusion: We need more studied in the future either surgically or immunologically to face this benign tumor to get less complications preoperative and postoperative to improve patients’ outcome. we need to know what’s is the next step of management.

Keywords: Craniopharyngioma; Adamantinomatous; Papillary Craniopharyngioma

References

1. Raimondi AJ and Rougerie J. “A critical review of personal experiences with craniopharyngioma: clinical history, surgical technique and operative results”. Pediatric Neurosurgery 21.2 (1994): 134-150.
2. Luschka H. “Der Gehirnhang und die Steissdruese des Menschen”. Berlin: G. Reimer (1860).
3. Saxer F. “Ein Beitrag zur Kenntniss der Dermoide und Teratome”. Ziegler's Beitr (1902).
4. Erdheim J. “Über hypophysengangsgeschwulste und hirmcholesteatome”. Sitzungsb Kais Akad Wissen Math Naturw Klin 113 (1904): 537-726.
5. Cushing H. “The craniopharyngioma Intralcranial tumors”. London: Bailliere, Tindal and Cox (1932): 93-98.
6. Susman W. “Embryonic epithelial rests in the pituitary”. British Journal of Surgery 19.76 (1932): 571-576.
7. Parisi JE and Mena H. “Nonglial tumors”. Principles and practice of neuropathology”. 1st ed. St. Louis, MO: Mosby (1993): 203-266.
8. Matson DD and Crigler JF. “Management of craniopharyngioma in childhood”. Journal of Neurosurgery 30.4 (1969): 377-390.
9. Schoenberg BS., et al. “The epidemiology of primary intracranial neoplasms of childhood. A population study”. Mayo Clinic Proceedings 51.1 (1976): 51-56.
10. Kuratsu J and Ushio Y. “Epidemiological study of primary intracranial tumors in childhood. A population based survey in Kumamoto Prefecture, Japan”. Pediatric Neurosurgery 25.5 (1996): 240-246.
11. Karavitaki N and Wass JA. “Non-adenomatous pituitary tumours”. Best Practice and Research Clinical Endocrinology and Metabolism 23 (2009): 651-665. 
12. Prabhu VC and Brown HG. “The pathogenesis of craniopharyngiomas”. Childs Nervous System 21 (2005): 622-627.
13. Holsken A., et al. “EGFR signaling regulates tum or cell migration in craniopharyngiomas”. Clinical Cancer Research 17 (2011): 4367-4377. 
14. Gump JM., et al. “Identification of targets for rational pharmacological therapy in childhood craniopharyngioma”. Acta Neuropathologica Communications 3 (2015): 30. 
15. Stache C., et al. “Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of surviving”. Neurosurgical Focus 41 (2016): E14.
16. Aylwin SJ., et al. “Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor”. Pituitary 19 (2016): 544-546. 
17. Cynthia Kassab., et al. “Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma”. Clinical Oncology and Research Journal 2.3 (2019): 2-8. 

Citation

Citation: Sameh Elmorsy Hassan Elmorsy. “Adult Craniopharyngioma Management: What’s the Next Step?”. Acta Scientific Neurology 3.3 (2020): 09-11.

Copyright

Copyright: © 2020 Sameh Elmorsy Hassan Elmorsy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.